Journal of vascular surgery. Venous and lymphatic disorders · 2026
Early endovenous laser ablation with 1940-nm wavelength for symptomatic marginal veins in pediatric Klippel-Trenaunay syndrome: A 4-year retrospective cohort study on safety, limb hypertrophy, and quality of life.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mahmoud Amr Abdelghaffar, Basta Mina Gamil Zekry, Hagag Mohamed Ahmed
Аннотация
BACKGROUND: Symptomatic marginal veins and progressive limb overgrowth are the hallmarks of Klippel-Trenaunay syndrome (KTS) and other phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum disorders. Data on endovenous laser ablation (EVLA) with modern wavelengths in pediatric populations with long-term follow-up remain limited.
METHODS: This retrospective single-arm cohort study was conducted at a tertiary university hospital. Forty-four pediatric patients with KTS (mean age, 12.5 years) with symptomatic marginal vein incompetence underwent EVLA with 1940-nm wavelength (4-6 W, 50-70 J/cm). Technical success, adverse events, limb circumference, vein quality-of-life scores, and reintervention rates were assessed over 4 years.
RESULTS: The technical success rate was 100% (44/44). Postprocedural pain (90.9%) and mild skin complications (95.5%) resolved almost entirely within 1 month (P < .001). The mean vein quality-of-life scores increased from 828.4 (standard deviation, 93.95) to 1562.1 (standard deviation, 162.40) at 4 years (P < .001). The leg and thigh circumferences decreased by 8.1 cm and 8.9 cm, respectively (P < .001). Late recanalization occurred in 4.5% of patients. No deep vein thrombosis or pulmonary embolism was recorded.
CONCLUSIONS: In this retrospective analysis, early 1940-nm EVLA for symptomatic marginal veins in pediatric KTS appears safe and highly effective, with sustained improvements in limb hypertrophy and quality of life at 4 years.
METHODS: This retrospective single-arm cohort study was conducted at a tertiary university hospital. Forty-four pediatric patients with KTS (mean age, 12.5 years) with symptomatic marginal vein incompetence underwent EVLA with 1940-nm wavelength (4-6 W, 50-70 J/cm). Technical success, adverse events, limb circumference, vein quality-of-life scores, and reintervention rates were assessed over 4 years.
RESULTS: The technical success rate was 100% (44/44). Postprocedural pain (90.9%) and mild skin complications (95.5%) resolved almost entirely within 1 month (P < .001). The mean vein quality-of-life scores increased from 828.4 (standard deviation, 93.95) to 1562.1 (standard deviation, 162.40) at 4 years (P < .001). The leg and thigh circumferences decreased by 8.1 cm and 8.9 cm, respectively (P < .001). Late recanalization occurred in 4.5% of patients. No deep vein thrombosis or pulmonary embolism was recorded.
CONCLUSIONS: In this retrospective analysis, early 1940-nm EVLA for symptomatic marginal veins in pediatric KTS appears safe and highly effective, with sustained improvements in limb hypertrophy and quality of life at 4 years.